PHARMAC is looking at widening access to three funded treatments – adalimumab, etanercept and tocilizumab – to enable more young people with juvenile idiopathic arthritis to benefit from these medicines.
PHARMAC is looking at funding two new medicines with substantial health benefits for up to 50,000 New Zealanders with type 2 diabetes.
PHARMAC has today advised healthcare professionals that a combined oral contraceptive, Brevinor-1 28 Day, is in short supply due to manufacturing delays.
Consultation has gone out today to health professionals and is available on PHARMAC’s website for anyone wanting to have their say about our annual tender process and a proposal to modify our contracting arrangements.
PHARMAC has today updated health care professionals that paracetamol 500 mg tablets for dispensing in pharmacies are in short supply due to global supply issues caused by COVID-19, and work is underway to secure more stock.
Most funded medicines will return to all-at-once dispensing because PHARMAC is removing most of the temporary dispensing restrictions put in place to manage supply during COVID-19. The change will be effective from midnight Friday 31 July 2020.
An independent review on the lamotrigine sole-supply decision has found that PHARMAC’s processes were evidence based and robust, and of a high standard.
From Monday a new medicine is being funded by PHARMAC which will help young children with cystic fibrosis digest their food more easily.
PHARMAC is placing temporary dispensing limits on all funded community medicines from Friday 27 March 2020.
Around 500 New Zealanders who have severe asthma will have access to a new medicine, mepolizumab, from next month.
PHARMAC is placing temporary dispensing limits on Government-funded paracetamol from Monday 9 March 2020.
New Zealanders with advanced breast cancer will be able to access palbociclib (marketed as Ibrance) from 1 April this year, which could stop or slow down the progression of their cancer.
PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) for people with cystic fibrosis.
PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living with type 2 diabetes
PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) for first-line and second-line treatment of certain types of breast cancer.
PHARMAC has published the Rare Disorders Subcommittee meeting records which recommends Spinraza (nusinersen), a medication for spinal muscular atrophy, is funded in New Zealand.
Thousands of New Zealanders with lymphoma, breast, ovarian and blood cancers will have more treatment options available to them in the New Year.
Patients taking lamotrigine who have concerns about the change can talk with their doctor about remaining on their current brand as PHARMAC has widened the criteria for lamotrigine exceptional circumstances.
The meningococcal ACWY vaccine will be available free from next month for young people in close living situations.
New Zealanders with chronic lymphocytic leukaemia will have another medicine option available to help them live longer from 1 December 2019.